Evidence map›Paper›PMID 26513413›Full record

ArticleBiomaterials2016

Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release.

Dandan Luo, Kevin A Carter, Aida Razi, Jumin Geng, Shuai Shao, Daniel Giraldo, Ulas Sunar, Joaquin Ortega, Jonathan F Lovell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dandan LuoDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.
Kevin A CarterDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.
Aida RaziDepartment of Biochemistry and Biomedical Sciences and M. G. DeGroote Institute for Infectious Diseases Research, McMaster University, Hamilton, ON, L8S4L8, Canada.
Jumin GengDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.
Shuai ShaoDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.
Daniel GiraldoDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.
Ulas SunarDepartment of Biomedical, Industrial & Human Factors Engineering, Wright State University, Dayton, OH 45435, USA.
Joaquin OrtegaDepartment of Biochemistry and Biomedical Sciences and M. G. DeGroote Institute for Infectious Diseases Research, McMaster University, Hamilton, ON, L8S4L8, Canada.
Jonathan F LovellDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA. Electronic address: jflovell@buffalo.edu.

Funding

Light-Triggered Drug Release in Primed Pancreatic TumorsR01EB017270 · NIBIB · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2021
$3.5M
Targeting Tumors with Resealable Nanovesicles Permeabilized by NIR LightDP5OD017898 · OD · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2017
$1.9M
Quantitative Endoscopic Imaging and Structured Light Delivery for Controlled DrugR21EB019147 · NIBIB · WRIGHT STATE UNIVERSITY · PI SUNAR, ULAS · 2014 to 2015
$412k
NIBIB NIH HHS R01 EB017270NIBIB NIH HHS R01EB017270NIBIB NIH HHS R21 EB019147NIBIB NIH HHS R21EB019147NIH HHS DP5 OD017898NIH HHS DP5OD017898
6 · The paper itself

Abstract

Stealth liposomes can be used to extend the blood circulation time of encapsulated therapeutics. Inclusion of 2 molar % porphyrin-phospholipid (PoP) imparted optimal near infrared (NIR) light-triggered release of doxorubicin (Dox) from conventional sterically stabilized stealth liposomes. The type and amount of PoP affected drug loading, serum stability and drug release induced by NIR light. Cholesterol and PEGylation were required for Dox loading, but slowed light-triggered release. Dox in stealth PoP liposomes had a long circulation half-life in mice of 21.9 h and was stable in storage for months. Following intravenous injection and NIR irradiation, Dox deposition increased ∼ 7 fold in treated subcutaneous human pancreatic xenografts. Phototreatment induced mild tumor heating and complex tumor hemodynamics. A single chemophototherapy treatment with Dox-loaded stealth PoP liposomes (at 5-7 mg/kg Dox) eradicated tumors while corresponding chemo- or photodynamic therapies were ineffective. A low dose 3 mg/kg Dox phototreatment with stealth PoP liposomes was more effective than a maximum tolerated dose of free (7 mg/kg) or conventional long-circulating liposomal Dox (21 mg/kg). To our knowledge, Dox-loaded stealth PoP liposomes represent the first reported long-circulating nanoparticle capable of light-triggered drug release.

Indexed as

Drug LiberationAnimalsCell Line, TumorCholesterolDoxorubicinFemaleHumansMice, NudeNeoplasmsPhospholipidsPhototherapyPolyethylene GlycolsPorphyrinsTemperatureCholesterolDoxorubicinliposomal doxorubicinPhospholipidsPolyethylene GlycolsPorphyrinsChemophototherapyChemotherapyDoxorubicinLiposomesPhototherapyPorphyrin-phospholipid

Identifiers

PMID26513413
PMCPMC4644481

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.